(Q50869969)

24 March 2018

title

Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. (English)

1 reference

24 March 2018

pneumococcal conjugate vaccine

1 reference

1 reference

based on heuristic

inferred from title

author name string

Sigurveig Th Sigurdardottir

1

1 reference

24 March 2018

Kimberly J Center

2

1 reference

24 March 2018

Katrin Davidsdottir

3

1 reference

24 March 2018

Vilhjalmur A Arason

4

1 reference

24 March 2018

Bjorn Hjalmarsson

5

1 reference

24 March 2018

Ragnheidur Elisdottir

6

1 reference

24 March 2018

Gunnhildur Ingolfsdottir

7

1 reference

24 March 2018

Robert Northington

8

1 reference

24 March 2018

Daniel A Scott

9

1 reference

24 March 2018

Ingileif Jonsdottir

10

1 reference

24 March 2018

language of work or name

English

0 references

publication date

2 December 2013

1 reference

24 March 2018

published in

Vaccine

1 reference

24 March 2018

volume

32

1 reference

24 March 2018

issue

3

1 reference

24 March 2018

page(s)

417-424

1 reference

24 March 2018

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

The potential indirect effect of conjugate pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Long-term protection in children with meningococcal C conjugate vaccination: lessons learned

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

High-throughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Test-based exact confidence intervals for the difference of two binomial proportions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Serotype-Specific Hyporesponsiveness to Pneumococcal Conjugate Vaccine in Infants Carrying Pneumococcus at the Time of Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

The advantage of mucosal immunization for polysaccharide-specific memory responses in early life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.11.029

10.1016/J.VACCINE.2013.11.029

7 January 2021

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018